Saving changes...

Done

Error

2019 ACCP Journal of Clinical Pharmacology Journal CE January | Inhibition of CYP2EI With Propylene Glycol Does Not Protect Against Hepatocellular Injury in Human Acetaminophen Daily-dosing Model

2019 ACCP Journal of Clinical Pharmacology Journal CE January | Inhibition of CYP2EI With Propylene Glycol Does Not Protect Against Hepatocellular Injury in Human Acetaminophen Daily-dosing Model

2019 ACCP Journal of Clinical Pharmacology Journal CE January | Inhibition of CYP2EI With Propylene Glycol Does Not Protect Against Hepatocellular Injury in Human Acetaminophen Daily-dosing Model

Michael Ganetsky, MD, Anders H.Berg, MD, PhD, Joshua J.Solano, MD, and Steven Salhanick, MD
Michael Ganetsky, MD, Anders H.Berg, MD, PhD, Joshua J.Solano, MD, and Steven Salhanick, MD
on behalf of American College of Clinical Pharmacology

$10.00 $ 10.00 $ 10.00

$ 10.00 $ 10.00 $ 10.00
$ 10.00 $ 10.00 $ 10.00
Normal Price: $10.00 $10.00

Review:

Launch date: 17 Jan 2019
Expiry Date: 31 Dec 2021

Last updated: 29 Jan 2019

Reference: 193148

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

Following the completion of this activity, learners will acquire further insight regarding the metabolic fate of acetaminophen (APAP) and the toxicity potential associated with metabolite formation. Learners will evaluate the potential of propylene glycol to be used as an APAP toxicity-limiting agent. This activity provides further insight related to CYP 450 enzymatic inhibition as a potential mechanism for toxicological management.

Objectives

Define the effects of propylene glycol on acetaminophen metabolite production
After completing this activity, the learner will be able to define the effects of propylene glycol on acetaminophen metabolite production.
Identify metabolic pathways associated with the fate of acetaminophen
After completing this activity, the learner will be able to identify metabolic pathways associated with the fate of acetaminophen.
Characterize the effect of treatments on changes in liver function tests
After completing this activity, the learner will be able to characterize the effect of treatments on changes in liver function tests.
Michael Ganetsky, MD, Anders H.Berg, MD, PhD, Joshua J.Solano, MD, and Steven Salhanick, MD

Author Information Play Video Bio

Michael Ganetsky, MD, Anders H.Berg, MD, PhD, Joshua J.Solano, MD, and Steven Salhanick, MD
on behalf of American College of Clinical Pharmacology

In the 1960s, a group of eminent physicians formulated the concept of an organization dedicated to a new branch of pharmacology that dealt with the effectiveness and safety of drugs in man. As a result of their efforts, the American College of Clinical Pharmacology (ACCP) was founded on September 11, 1969. Today, ACCP consists of a full spectrum of clinical pharmacology professionals from academia, industry, government and clinical settings who span the scope from research and drug development to patient-related care and who remain dedicated to advancing clinical pharmacology with the ultimate goal of enhancing patient care.

As an organization whose primary role is education, ACCP does not concentrate on any one aspect of the discipline. Rather, it seeks to address the educational needs of its diverse membership and all healthcare professionals, covering a range of topics that span the entire area of the interaction between drugs and humans. These areas include, but are not limited to, pharmaceutical chemistry, biochemistry, drug metabolism, pharmacokinetics, pharmacodynamics, pharmacometrics, pharmacogenomics clinical pharmacology practice in the outpatient and inpatient settings, human toxicology, drug interactions and clinical drug trials. The diversity of ACCP is expressed not only in the composition of its membership, but also in its leadership. Maintaining a balance of elected Regents and Officers from all pertinent professional backgrounds ensures that ACCP remains attuned to the needs of all professionals engaged in the practice of or with a strong interest in clinical pharmacology, from the research laboratory (academic and industrial) to the classroom, and from clinical trials to improved patient care.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Continuing Medical Education (ACCME)
  • 1.00 Credits
  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.00 Hours -
    Exam Pass Rate: 75

Faculty and Disclosures

Joseph Bertino, PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc

Joseph Bertino, PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc

Nothing to disclose.
Steven Crosby, MA, BSP, RPh, FASCP, Assistant Dean & Associate Professor of Pharmacy Practice, MCPHS University

Steven Crosby, MA, BSP, RPh, FASCP, Assistant Dean & Associate Professor of Pharmacy Practice, MCPHS University

Nothing to disclose.
Jomy George, PharmD, BCPS, AQ-ID, Director (Acting), Natl Inst of Health, Clinical  Pharmacokinetics Unit, Pharmacy

Jomy George, PharmD, BCPS, AQ-ID, Director (Acting), Natl Inst of Health, Clinical Pharmacokinetics Unit, Pharmacy

Nothing to disclose.

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error